Mercy BioAnalytics Stock

Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.

Sign up today and learn more about Mercy BioAnalytics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Mercy BioAnalytics Stock

Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer. It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer. Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018.

Funding History

January 2021$27.3M
April 2023$41.0M

Management

CSO & Co-Founder

Joseph Sedlak

Chief Operating Officer

Dawn Mattoon

CEO & Co-Founder

Paul Blavin

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo